论文部分内容阅读
选取167例病人,以HbA1c作为效果衡量指标,运用成本效果分析方法评价胰岛素三种给药方案(A组:短效+中效动物胰岛素;B组:诺和灵R+N;C组:诺和锐+来得时)治疗老年糖尿病。结果:3种方案的有效率分别为80.8%、94.7%、98.2%,其治疗总成本分别为184.29元、571.32元和1312.33元;使HbA1c下降一个百分点,费用分别为38.31元、93.81元和191.86元。敏感度分析显示经济学分析结果稳定。结论:从药物经济学的角度分析,诺和灵R+N方案为佳;诺和锐+来得时疗效最好,但成本效果比最高。
167 patients were enrolled in this study. HbA1c was used as a measure of efficacy and the three dosage regimens of insulin were evaluated by cost-effectiveness analysis (group A: short-acting and mid-acting animals, insulin; group B: norepinephrine R + N; group C: And sharp + come when) treatment of elderly diabetes. Results: The effective rates of the three regimens were 80.8%, 94.7% and 98.2%, respectively. The total cost of treatment was 184.29 yuan, 571.32 yuan and 1312.33 yuan respectively. The HbA1c was decreased by 1 percentage point with costs of 38.31 yuan, 93.81 yuan and 191.86 yuan respectively yuan. Sensitivity analysis shows that the economic analysis results are stable. Conclusion: From the perspective of pharmacoeconomics, the Novo-R + N regimen is better; NovoRay + is the best, but the cost-effective is the highest.